Top

Journal of Endocrinological Investigation

Published in:

01-04-2019 | Original Article

Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy

Authors: M. Marinò, G. Rotondo Dottore, I. Ionni, G. Lanzolla, E. Sabini, D. Ricci, A. Sframeli, B. Mazzi, F. Menconi, F. Latrofa, P. Vitti, C. Marcocci, L. Chiovato

Published in: Journal of Endocrinological Investigation | Issue 4/2019

Abstract

Background

A role of the insulin-like growth factor-1 receptor (IGF-1R) in the pathogenesis of Graves’ orbitopathy (GO) has been proposed, but the existence and function of anti-IGF-1R-antibodies (IGF-1R-Abs) are debated.

Methods

We designed a cross-sectional investigation to measure serum IGF-1R-Abs by a commercial assay in consecutive patients with Graves’ disease (GD) compared with healthy subjects and patients with autoimmune thyroiditis (AT). A total of 134 subjects were screened including 27 healthy subjects, 80 GD patients (54 of whom with GO), and 27 AT patients. The main outcome measure was the prevalence of positive serum IGF-1R-Abs in GO, compared with GD without GO and with the other study groups.

Results

Having established a cut-off value at 55.2 ng/ml for positive tests, positive IGF-1R-Abs were more frequent in GD (25%), than in AT (3.7%, P = 0.003) and healthy subjects (0%, P = 0.006). Within GD, there was no difference between patients with or without GO. Serum levels of IGF-1R-Abs differed across the study population (P < 0.0001), reflecting their higher concentrations in GD (P < 0.0001 vs both AT and healthy subjects), but with no difference between patients with or without GO. In patients with GO, there was an inverse correlation between serum IGF-1R-Abs and CAS (R = − 0.376, 95% CI: from − 0.373 to − 0.631; P = 0.005), the significance of which remains to be investigated.

Conclusions

Serum autoantibodies against the IFG-1R are present in one-fourth of GD patients, regardless of the presence of GO. Further functional studies are needed to investigate the significance of their inverse correlation with GO activity.

Bartalena L, Baldeschi L, Boboridis K, Eckstein A, Kahaly GJ, Marcocci C, Perros P, Salvi M, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2016) The 2016 European Thyroid Association/European Group on Graves’ orbitopathy guidelines for the management of Graves’ orbitopathy. Eur Thyroid J 5:9–26CrossRefPubMedPubMedCentral

Piantanida E, Tanda ML, Lai A, Sassi L, Bartalena L (2013) Prevalence and natural history of Graves’ orbitopathy in the XXI century. J Endocrinol Investig 36:444–449

Leo M, Menconi F, Rocchi R, Latrofa F, Sisti E, Profilo MA, Mazzi B, Albano E, Nardi M, Vitti P, Marcocci C, Marinò M (2015) Role of the underlying thyroid disease on the phenotype of Graves’ orbitopathy in a tertiary referral center. Thyroid 25:347–351CrossRefPubMed

Bahn RS (2015) Current insights into the pathogenesis of Graves’ ophthalmopathy. Horm Metab Res 47:773–778CrossRefPubMed

Mohyi M, Smith TJ (2018) IGF-I receptor and thyroid-associated ophthalmopathy. J Mol Endocrinol 61:T29–T43CrossRefPubMed

Smith TJ, Hegedüs L, Douglas RS (2012) Role of insulin-like growth factor-1 (IGF-1) pathway in the pathogenesis of Graves’ orbitopathy. Best Pract Res Clin Endocrinol Metab 26:291–302CrossRefPubMedPubMedCentral

Tsui S, Naik V, Hoa N, Hwang CJ, Afifiyan NF, Sinha Hikim A, Gianoukakis AG, Douglas RS, Smith TJ (2008) Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves’ disease. J Immunol 181:4397–4405CrossRefPubMedPubMedCentral

Smith TJ, Tsai CC, Shih MJ, Tsui S, Chen B, Han R, Naik V, King CS, Press C, Kamat S, Goldberg RA, Phipps RP, Douglas RS, Gianoukakis AG (2008) Unique attributes of orbital fibroblasts and global alterations in IGF-1 receptor signaling could explain thyroid-associated ophthalmopathy. Thyroid 18:983–988CrossRefPubMedPubMedCentral

Weightman DR, Perros P, Sherif IH, Kendall-Taylor P (1993) Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16:251–577CrossRefPubMed

10.

Pritchard J, Horst N, Cruikshank W, Smith TJ (2002) Igs from patients with Graves’ disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 168:942–950CrossRefPubMed

11.

Pritchard J, Han R, Horst N, Cruikshank WW, Smith TJ (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves’ disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170:6348–6354CrossRefPubMed

12.

Krieger CC, Place RF, Bevilacqua C, Marcus-Samuels B, Abel BS, Skarulis MC, Kahaly GJ, Neumann S, Gershengorn MC (2016) TSH/IGF-1 receptor cross talk in Graves’ ophthalmopathy pathogenesis. J Clin Endocrinol Metab 101:2340–2347CrossRefPubMedPubMedCentral

13.

Minich WB, Dehina N, Welsink T, Schwiebert C, Morgenthaler NG, Köhrle J, Eckstein A, Schomburg L (2013) Autoantibodies to the IGF1 receptor in Graves’ orbitopathy. J Clin Endocrinol Metab 98:752–760CrossRefPubMed

14.

Wiersinga WM (2011) Autoimmunity in Graves’ ophthalmopathy: the result of an unfortunate marriage between TSH receptors and IGF-1 receptors? J Clin Endocrinol Metab 96:2386–2394CrossRefPubMed

15.

Krieger CC, Neumann S, Marcus-Samuels B, Gershengorn MC (2017) TSHR/IGF-1R cross-talk, not IGF-1R stimulating antibodies, mediates Graves’ ophthalmopathy pathogenesis. Thyroid 27:746–747CrossRefPubMedPubMedCentral

16.

Smith TJ, Janssen JAMJL et al (2017) Response to Krieger et al. Re: “TSHR/IGF-1R cross-talk, not IGF-1R stimulating antibodies, mediates Graves’ ophthalmopathy pathogenesis” (Thyroid 2017;27:746–747). Thyroid 27:1458–1459CrossRefPubMedPubMedCentral

17.

Neumann S, Gershengorn MC (2017) Rebuttal to Smith and Janssen. Thyroid 27:746–747. https://doi.org/10.1089/thy.2017.0281 (1459–1460) CrossRefPubMedPubMedCentral

18.

Marcus-Samuels B, Krieger CC, Boutin A, Kahaly G, Neumann S, Gershengorn MC (2018) Evidence that Graves’ ophthalmopathy immunoglobulins do not directly activate IGF-1 receptors. Thyroid 28:650–655CrossRefPubMedPubMedCentral

19.

Varewijck AJ, Boelen A, Lamberts SW, Fliers E, Hofland LJ, Wiersinga WM, Janssen JA (2013) Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves’ ophthalmopathy. J Clin Endocrinol Metab 98:769–776CrossRefPubMed

20.

Smith TJ, Kahaly GJ, Ezra DG, Fleming JC, Dailey RA, Tang RA, Harris GJ, Antonelli A, Salvi M, Goldberg RA, Gigantelli JW, Couch SM, Shriver EM, Hayek BR, Hink EM, Woodward RM, Gabriel K, Magni G, Douglas RS (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376:1748–1761CrossRefPubMedPubMedCentral

21.

Piantanida E, Bartalena L (2017) Teprotumumab: a new avenue for the management of moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Invest 40:885–887CrossRefPubMed

22.

Bartalena L, Veronesi G, Krassas GE, Wiersinga WM, Marcocci C, Marinò M, Salvi M, Daumerie C, Bournaud C, Stahl M, Sassi L, Azzolini C, Boboridis KG, Mourits MP, Soeters MR, Baldeschi L, Nardi M, Currò N, Boschi A, Bernard M, von Arx G, Perros P, Kahaly GJ (2017) Does early response to intravenous glucocorticoids predict the final outcome in patients with moderate-to-severe and active Graves’ orbitopathy? J Endocrinol Investig 40:547–553CrossRef

23.

Rotondo Dottore G, Torregrossa L, Caturegli P, Ionni I, Sframeli A, Sabini E, Menconi F, Piaggi P, Sellari-Franceschini S, Nardi M, Latrofa F, Vitti P, Marcocci C, Basolo F, Marinò M (2018) Association of T and B cells infiltrating orbital tissues in Graves orbitopathy with Graves orbitopathy activity. A possible explanation for GO response to immunosuppressive treatments. JAMA Ophthalmol 136:613–619CrossRefPubMedPubMedCentral

24.

Sellari-Franceschini S, Rocchi R, Marinò M, Bajraktari A, Mazzi B, Fiacchini G, Lepri P, Dallan I, Vitti P, Marcocci C (2018) Rehabilitative orbital decompression for Graves’ orbitopathy: results of a randomized clinical trial. J Endocrinol Investig (in press)

25.

Kahaly GJ, Riedl M, König J, Pitz S, Ponto K, Diana T, Kampmann E, Kolbe E, Eckstein A, Moeller LC, Führer D, Salvi M, Curro N, Campi I, Covelli D, Leo M, Marinò M, Menconi F, Marcocci C, Bartalena L, Perros P, Wiersinga WM, European Group on Graves’ Orbitopathy (EUGOGO) (2018) Combined mycophenolate + prednisolone therapy is more effective than prednisolone in active and moderate-to-severe Graves’ orbitopathy—a randomized, observer blind, multicenter trial. Lancet Diabetes Endocrinol 6:287–298CrossRefPubMed

26.

Profilo MA, Sisti E, Marcocci C, Vitti P, Pinchera A, Nardi M, Rocchi R, Latrofa F, Menconi F, Altea MA, Leo M, Rago T, Marinò M (2013) Thyroid volume and severity of Graves’ orbitopathy. Thyroid 23:97–102CrossRefPubMed

27.

Sabini E, Mazzi B, Profilo MA, Mautone T, Casini G, Rocchi R, Ionni I, Menconi F, Leo M, Nardi M, Vitti P, Marcocci C, Marinò M (2018) Serum high cholesterol is a novel risk factor for Graves’ orbitopathy (GO): results of a cross-sectional study. Thyroid 28:386–394CrossRefPubMed

28.

Mourits MP, Lombardo SH, van der Sluijs FA, Fenton S (2004) Reliability of exophthalmos measurement and the exophthalmometry value distribution in a healthy Dutch population and in Graves’ patients. An exploratory study. Orbit 23:161–168CrossRefPubMed

29.

Bilen H, Gullulu G, Akcay G (2007) Exophthalmometric values in a normal Turkish population living in the northeastern part of Turkey. Thyroid 17:525–528CrossRefPubMed

30.

Kashkouli MB, Nojomi M, Parvaresh MM, Sanjari MS, Modarres M, Noorani MM (2008) Normal values of Hertel exophthalmometry in children, teenagers, and adults from Tehran, Iran. Optom Vis Sci 85:1012–1017CrossRefPubMed

31.

Beden U, Ozarslan Y, Oztürk HE, Sönmez B, Erkan D, Oge I (2008) Exophthalmometry values of Turkish adult population and the effect of age, sex, refractive status, and Hertel base values on Hertel readings. Eur J Ophthalmol 18:165–171CrossRefPubMed

32.

Chan W, Madge SN, Senaratne T, Senanayake S, Edussuriya K, Selva D, Casson RJ (2009) Exophthalmometric values and their biometric correlates: the Kandy Eye Study. Clin Exp Ophthalmol 37:496–502CrossRefPubMed

33.

Marcocci C, Marinò M (2005) Thyroid directed antibodies. In: Braverman LE, Utiger RD (eds) Werner and Ingbar’s the thyroid: a fundamental and clinical text, 9th edn. Lippincott, Williams & Wilkins, Philadelphia, pp 360–372

34.

Leo M, Marcocci C, Pinchera A, Nardi M, Megna L, Rocchi R, Latrofa F, Altea MA, Mazzi B, Sisti E, Profilo MA, Marinò M (2012) Outcome of Graves’ orbitopathy after total thyroid ablation and glucocorticoid treatment: follow-up of a randomized clinical trial. J Clin Endocrinol Metab 97:E44–48CrossRefPubMed

35.

Menconi F, Leo M, Vitti P, Marcocci C, Marinò M (2015) Thyroid ablation in Graves’ orbitopathy. J Endocrinol Investig 38:809–815CrossRef

36.

Perros P, Hegedüs L, Bartalena L, Marcocci C, Kahaly GJ, Baldeschi L, Salvi M, Lazarus JH, Eckstein A, Pitz S, Boboridis K, Anagnostis P, Ayvaz G, Boschi A, Brix TH, Currò N, Konuk O, Marinò M, Mitchell AL, Stankovic B, Törüner FB, von Arx G, Zarković M, Wiersinga WM (2017) Graves’ orbitopathy as a rare disease in Europe: a European Group On Graves’ Orbitopathy (EUGOGO) position statement. Orphanet J Rare Dis 12:72CrossRefPubMedPubMedCentral

37.

Eckstein AK, Plicht M, Lax H, Neuhäuser M, Mann K, Lederbogen S, Heckmann C, Esser J, Morgenthaler NG (2006) Thyrotropin receptor autoantibodies are independent risk factors for Graves’ ophthalmopathy and help to predict severity and outcome of the disease. J Clin Endocrinol Metab 91:3464–3470CrossRefPubMed

38.

Sisti E, Menconi F, Leo M, Profilo MA, Mautone T, Mazzi B, Rocchi R, Latrofa F, Nardi M, Vitti P, Marcocci C, Marinò M (2015) Long-term outcome of Graves’ orbitopathy following high-dose intravenous glucocorticoids and orbital radiotherapy. J Endocrinol Investig 38:661–668CrossRef

Title: Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves’ disease and Graves’ orbitopathy
Authors: M. Marinò
G. Rotondo Dottore
I. Ionni
G. Lanzolla
E. Sabini
D. Ricci
A. Sframeli
B. Mazzi
F. Menconi
F. Latrofa
P. Vitti
C. Marcocci
L. Chiovato
Publication date: 01-04-2019
Publisher: Springer International Publishing
Published in: Journal of Endocrinological Investigation / Issue 4/2019
Electronic ISSN: 1720-8386
DOI: https://doi.org/10.1007/s40618-018-0943-8

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2019

PETC/CT with 18F-Choline localizes hyperfunctioning parathyroid adenomas equally well in normocalcemic hyperparathyroidism as in overt hyperparathyroidism

Clinical features, diagnosis and therapy of pituicytoma: an update

Effects of mandatory salt iodization on breast milk, urinary iodine concentrations, and thyroid hormones: is iodine deficiency still a continuing problem?

Gender difference in authorship of clinical practice guidelines and position statements in endocrinology

Genotype–phenotype correlation, gonadal malignancy risk, gender preference, and testosterone/dihydrotestosterone ratio in steroid 5-alpha-reductase type 2 deficiency: a multicenter study from Turkey

Use of administrative health databases to estimate incidence and prevalence of acromegaly in Piedmont Region, Italy

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials